Third after Hugel and Huons: Eannabio's 'Eannabio' penetrates China's botulinum toxin market
Predicted impact: Low
Botulinum toxin China market entry; sales size not disclosed.
Huons휴온스
243070 · KOSDAQ · ₩243070 · 휴온스
₩17,030▼ ₩300 (1.73%)End-of-day · Oct 29, 2026 · End-of-day prices.
Huons Unveils Promising Preclinical Results for Crohn's Disease Fibrosis Drug Candidate
Predicted impact: Low
Preclinical drug results with no clinical or revenue milestone.
Huons completes preclinical trial showing intestinal fibrosis inhibition effect for Crohn's disease new drug
Predicted impact: Low
Preclinical Crohn's result already reported in recent items; early-stage research only.
Huons Presents Non-clinical Results of Fibrostenotic Crohn's Disease Treatment Candidate in Poster at European Digestive Disease Meeting
Predicted impact: Low
Conference poster on preclinical results; early-stage with no financial size.
Huons Confirms Potential of Own Drug Candidate to Suppress Intestinal Fibrosis in Crohn's Disease
Predicted impact: Low
Early-stage drug candidate research result; pipeline news with no revenue impact yet.
HUONS Group proves research achievements with consecutive intellectual property acquisitions…"Sustainable growth in the future"
Predicted impact: Low
Intellectual property acquisitions are routine and not quantified.
Huons Lab Expands Application of 'HyDiffuse' Under SC Formulation Change
Predicted impact: Low
Also known as: Huons / 휴온스 / 243070 / KRX:243070
Source: KRX statistical information